Compare MLCI & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MLCI | GRML |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 21 | 5 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 34.9M |
| IPO Year | N/A | 2022 |
| Metric | MLCI | GRML |
|---|---|---|
| Price | $3.07 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.6K | ★ 7.7M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.68 | $0.16 |
| 52 Week High | $8.68 | $0.55 |
| Indicator | MLCI | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 44.53 |
| Support Level | $2.70 | $0.16 |
| Resistance Level | $3.13 | $0.30 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 6.56 | 31.13 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.